Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Adobe Systems Inc (ADBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Adobe Systems Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Adobe Systems Inc trades at $220.64 (market cap $88.06B). The key difference: Adobe Systems Inc is far larger — about 19.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ADBE | |
|---|---|---|
Market Cap | $4.49B | $88.06B |
Sector | Health | Technology |
52-Week High | $28.06 | $382.24 |
52-Week Low | $20.06 | $193.41 |
Enterprise Value | $3.69B | $89.50B |
Volume | — | 5,187,646 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Adobe Inc. (ADBE) trades at $220.94, up 1.32% with strong fundamentals including 29.99% net margin and consistent earnings beats. Technical indicators show bullish momentum with support at $218 and resistance at $228. Recent news highlights institutional buying despite AI competition concerns, while cash flow remains robust at $10.03B from operations in 2025.
Outlook remains positive with a $246.75 analyst target, though risks include AI disruption and CEO transition. Valuation appears attractive with P/E of 12.67, supporting a buy case for long-term growth investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →
